Further rationale for optimal combined modality treatments
Oncotarget
.
2017 Apr 18;8(16):25831-25832.
doi: 10.18632/oncotarget.16117.
Authors
Robert J Griffin
1
,
Ruud P M Dings
1
,
Issam Makhoul
2
Affiliations
1
Department of Radiation Oncology, Radiation Biology Division, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
2
Department of Internal Medicine, Hematology/Oncology Division, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
PMID:
28415727
PMCID:
PMC5432217
DOI:
10.18632/oncotarget.16117
No abstract available
Keywords:
anti-angiogenic agent; radiotherapy; re-oxygenation; sunitinib.
Publication types
News
Comment
MeSH terms
Combined Modality Therapy
Humans
Neoplasms*